HEALTH TECHNOLOGY

Axonics® Expands Sacral Neuromodulation Intellectual Property Portfolio

Axonics, Inc. | August 18, 2022 | Read time : 01:00 min

Axonics® Expands

Axonics, Inc. a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, announced that in the last twelve months, the United States Patent and Trademark Office has granted eight patents and allowed four patent applications related to the company’s sacral neuromodulation technology.

The patents and allowed applications are part of Axonics’ patent portfolio and represents technology internally developed by the company covering a range of subject matter that includes the Axonics external trial system, tined lead, implantable neurostimulator, clinician programmer, wireless charging system and patient remote control.

Axonics is committed to developing best-in-class technology to serve the unmet needs of the millions of adults suffering from incontinence. The volume, subject matter diversity, and breadth of these patents demonstrate the investment in innovation that Axonics continues to make in sacral neuromodulation technology,”

Raymond W. Cohen, chief executive officer

About Axonics
Based in Irvine, Calif., Axonics is a global medical technology company that is developing and commercializing novel products for adults with bladder and bowel dysfunction. Axonics recently ranked No. 1 on the 2021 Deloitte Technology Fast 500™ and the 2022 Financial Times ranking of the 500 fastest growing companies in the Americas.

Axonics sacral neuromodulation (SNM) systems provide adults suffering from overactive bladder and/or fecal incontinence with long-lived, easy to use, safe, clinically effective therapy. In addition, the company’s best-in-class urethral bulking hydrogel, Bulkamid®, provides safe and durable symptom relief to women with stress urinary incontinence (SUI). Overactive bladder affects an estimated 87 million adults in the U.S. and Europe, with an additional 40 million adults estimated to suffer from fecal incontinence. SUI affects an estimated 29 million women in the U.S. alone. Axonics’ clinically proven products are offered at hundreds of medical centers across the U.S. and abroad. Reimbursement coverage is well established in the U.S. and is a covered service in most European countries. 

Spotlight

Welcome to the BEAT. My name is Kevin Prosser and I am your new Director of Community Relations at Oneida Healthcare. My goal is to make the BEAT a reliable, engaging source of OHC information for you and everyone who is part of our “Circle of Care.” To achieve this goal, I need you.

Spotlight

Welcome to the BEAT. My name is Kevin Prosser and I am your new Director of Community Relations at Oneida Healthcare. My goal is to make the BEAT a reliable, engaging source of OHC information for you and everyone who is part of our “Circle of Care.” To achieve this goal, I need you.

Related News

HEALTH TECHNOLOGY

MobileSmith Health Announces Go-Live at CHI St. Vincent Infirmary

MobileSmith | September 15, 2022

MobileSmith a leading provider of cutting-edge mobile software solutions, announces delivery and live status of their PeriOp solution at CHI St. Vincent Infirmary. MobileSmith Health is proud to partner with CHI St. Vincent in improving throughput and clinical care for surgical patients using the PeriOp solution. This toolset provides visibility of patient activities and status to the clinical team preparing to welcome patients for surgery. The adherence dashboard helps clinicians focus on the patients who need the most help. Patients, in turn, get education about their procedure, complete necessary preoperative tasks, and are better prepared to manage their care at home. "We are thrilled to partner with CHI St. Vincent and their innovative team. Our work addresses patient outcomes while improving patient satisfaction. It also reduces the workload of clinical staff by automating routine tasks and improving predictability in patient throughput," Chris Caramanico, Chief Executive Officer of MobileSmith Health "The MobileSmith Health team has been a pleasure to work with. We have a shared vision and passion to make healthcare communication to the patient reliable and more efficient. The combination of MobileSmith Health and our talented and innovative team at CHI St. Vincent are proving that we can make a difference in the daily work of many clinicians while improving patient outcomes," said Dr. Jill Flaxman, Medical Director of Perioperative Services. About MobileSmith MobileSmith Health is a digital health technology company focused on increasing efficiency and improving outcomes by providing clinicians with modern pre- and post-surgery dashboard, showing how patients participate in their own care. PeriOp, MobileSmith Health’s patient app, connects providers to their patients, streamlines information, simplifies surgery preparation and discharge and reduces complications. PeriOp by MobileSmith Health makes the science, process and oversight simple.

Read More

HEALTH TECHNOLOGY

Medical Device Innovation Consortium Launches Initiative to Improve Accuracy of Next Generation Sequencing-Based Cancer Diagnostics

MDIC | August 23, 2022

The Medical Device Innovation Consortium formally launched its Somatic Reference Samples Initiative with a pilot project to improve the validation and regulatory review process for cancer diagnostics based on next generation sequencing. MDIC will lead a collaboration with the U.S. Food and Drug Administration the National Institute of Standards and Technology, National Institutes of Health and industry stakeholders to manufacture, validate, and distribute SRSs to simplify and support validation of NGS-based cancer diagnostics. The initiative also includes the goal to create a publicly available global genomic data resource library of datasets with the potential to be used by sponsors and regulators. “NGS is a powerful technology enabling breakthroughs in diagnostics and ultimately therapeutics. These diagnostic tests need to be validated for accurate clinical use, and reference samples are essential to the validation process. But well-characterized and widely accepted reference materials do not exist for NGS-based diagnostics, complicating the development and validation process. Through the MDIC SRS Initiative, we are developing reference samples and data sets that can be used globally by test developers and regulators to bring more consistency to NGS-based cancer diagnostic development, increasing the confidence and accuracy of these tests, which will ultimately lead to more accuracy in diagnosis and treatment for patients.” Andrew Fish, President and CEO, MDIC “There is a need for appropriately consented, highly characterized, and broadly available reference materials that may improve the accuracy, reliability, and transparency of NGS-based oncology tests and support the generation of validation data for use in regulatory submissions. The reference samples and datasets being created by the MDIC Somatic Reference Samples Initiative can help fulfill this need,” said Wendy Rubinstein, MD, PhD, Director, Personalized Medicine, Center for Devices and Radiological Health, U.S. Food and Drug Administration. Horizon Discovery, a PerkinElmer company, is conducting the development and manufacture of these reference samples. The goal of this pilot project is to individually engineer 10 gene variants clinically associated with cancer into a highly characterized human cell line – GM24385 using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) technology resulting in ten edited human cell lines, each containing one gene variant clinically associated with one or more specific cancers. The cell lines, containing confirmed sequences, will be combined and available in FFPE format. The fully characterized reference samples will be commercially available to the end users from Horizon and the characterization data will be accessible through public databases, including precisionFDA, an FDA-sponsored site for data information, sequencing, and bioinformatics. NIST’s involvement in this work is to foster understanding.* “As our collaboration validates the MDIC SRS samples, we will also learn and build best practices to improve the efficiency and sustainability of reference sample validation and dataset generation in general. This project is a major step in the development and optimization of new sequencing technologies and the translation of DNA sequencing to clinical applications for diagnosing and treating cancer,” said Justin Zook, PhD, Co-Leader, Biomarker and Genomic Sciences Group, National Institute of Standards and Technology. MDIC’s SRS project began as a working group in 2018, representing more than forty stakeholders with a mission to address the gap in reference material for NGS-based diagnostic tests. The initial output of this working group, MDIC’s SRS Landscape Analysis, published in 2019, was a comprehensive catalog of existing clinically relevant cancer variants and available reference samples. Based on the unmet needs discovered through the SRS Landscape Analysis, the SRS Initiative has prioritized a subset of ten variants to be engineered into reference samples for the pilot project. In addition to the utility of these samples in development, validation, and regulatory review, these samples potentially have value in reimbursement decisions, post-market monitoring and informing the path forward for addition SRS. The work in the SRS Initiative is funded in part by the Gordon and Betty Moore Foundation the National Philanthropic Trust, Illumina, and Quidel. Affiliation with a commercial product does not imply recommendation or endorsement by the National Institute of Standards and Technology, nor does it imply that the materials or equipment identified are necessarily the best available for the purpose. About MDIC Founded in 2012, the Medical Device Innovation Consortium is the first public-private partnership created with the sole objective of advancing medical device regulatory science throughout the total product life cycle. MDIC’s mission is to transform health care into human care. Collaborating with our partners to advance science, we enable transformational medical technology to shape the world we want to live in and make that world possible by shortening the path from innovation to safety to access.

Read More

HEALTH TECHNOLOGY

LHC Group to acquire home health provider in Georgia

LHC Group, Inc. | August 17, 2022

LHC Group announced an agreement to purchase Three Rivers Home Health, a provider headquartered in Eastman, Ga. The acquisition includes nine total locations – expanding LHC Group's service footprint in 36 counties in the Certificate of Need state of Georgia. The acquisition is expected to close in the fourth quarter of 2022, subject to customary closing conditions. LHC Group expects annualized revenue from this purchase of approximately $12 million and that it will not materially affect its 2022 diluted earnings per share. Three Rivers Home Health will continue operating under its current name and from its present locations. There will be no interruption in the care provided to patients. Three Rivers Founder and President for the last 43 years, Kaye B. Smith, RN, said: "It is time for us to step aside and allow Three Rivers to become part of a larger organization. This transaction will make it possible for our employees to have greater opportunities and to continue providing the high-quality care they do every day." LHC Group is a leading national provider of in-home healthcare services. In addition to expanding LHC Group's service area, this acquisition aligns with the company's co-location strategy to provide multiple in-home healthcare services in certain markets, as well as its strategy of retaining and operating under a family of well-known local brands. "This is a great opportunity to serve more patients and families in Georgia with the quality in-home healthcare they want and deserve. Our new team members at Three Rivers have earned an outstanding reputation for the service they provide. Together, we will help ensure greater access to care in the patient's preferred setting – their home." Keith G. Myers, LHC Group's chairman and CEO About LHC Group, Inc. LHC Group, Inc. is a national provider of in-home healthcare services and innovations for communities around the nation, offering quality, value-based healthcare to patients primarily within the comfort and privacy of their home or place of residence. The company's 29,000 employees deliver home health, hospice, home- and community-based services, and facility-based care in 37 states and the District of Columbia – reaching 68 percent of the U.S. population aged 65 and older. Through Imperium Health, the company's ACO management and enablement company, LHC Group helps partners improve both savings and patient outcomes with a value-based approach. As the preferred joint venture partner for more than 400 leading U.S. hospitals and health systems, LHC Group works in cooperation with providers to customize each partnership and reach more patients and families with an effective and efficient model of care.

Read More